The Real Value of AI and Digital Innovation in Medtech and Biopharma

The healthcare world is buzzing with the potential of artificial intelligence (AI). While many debate whether AI will disrupt or deliver, in medtech and biopharma, the value proposition is becoming clear: AI and digital innovation are fundamentally reshaping how therapies are developed, delivered, and evaluated—with the patient experience at the core.

The Real Value for Medtech and Biopharma – AI-Powered Digital Connectivity

Across the sector, four high-impact areas have emerged where AI and digital technologies are proving especially valuable:

1. Accelerated R&D and Smarter Clinical Trials
   AI-driven platforms support target identification, simulate trial protocols, optimize patient matching, and streamline enrollment, significantly reducing cost and time to market [1][2].
2. Precision Medicine and Personalized Therapies
   AI enables deep insights from genomic, behavioral, and real-world datasets to design more tailored therapeutic regimens [3].
3. Operational Efficiencies and Cost Reductions
   From predictive inventory management to automated manufacturing quality control, AI improves performance and reduces waste.
4. Value-Based Care and Market Differentiation
   AI-enhanced real-world data enables manufacturers to better demonstrate therapeutic value, facilitating favorable reimbursement and improved access [4].

Among these, digital connectivity—linking the patient, prescriber, payer, and manufacturer—is emerging as the key differentiator in delivering both measurable outcomes and scalable value.

AI-Powered Digital Connectivity: The Next Medtech / Biopharma Frontier

AI-powered digital connectivity enhances therapeutic delivery by tightly integrating all ecosystem stakeholders.

Picture a new model where:

• The patient receives digital prompts, support, and monitoring through a companion app.
• The prescriber, with consent, receives real-time data on adherence, tolerance, and outcomes.
• The payer is able to validate treatment efficacy using AI-interpreted real-world data streams [5].
• The biopharma manufacturer accesses anonymized outcome data to improve future therapies [6].

These capabilities are delivered through platforms like digital therapeutics (DTx), remote patient monitoring (RPM), and connected medical devices [1][2].

Figure 1: Biopharma & Medtech AI / Digital Innovation

Patient Adherence Confirmation: Historical Approaches and Limits

Historically, patient adherence tracking relied on:

• In-clinic administration
• Digital pills with embedded sensors (ingestible trackers)
• Manual patient diaries or self-reporting

These innovations from the past failed to scale due to reasons like privacy concerns, cost, and suboptimal user experience [4]. Ingestible trackers, in particular, faced resistance from both patients and providers, but they had the capability of more automatically confirming patient adherence and generating data.

In contrast, digital companion applications (apps) offer a less intrusive and more patient-friendly approach. When utilized via smart devices patients are familiar with, these tools can:

• Alert patients when it’s time to take their medication
• Log biometric or behavioral data
• Pair with biometric sensors worn by the patient
• Generate feedback for both the patient and their care team
• Support providers and payers with adherence insights [7]

Tools like Rejoyn, a prescription digital therapeutic (PDT) approved for depression, show that connected digital tools are gaining regulatory traction and patient acceptance [8].

Another innovative patient tool, Sprints by Carrot Fertility, is recently available, and allows patients to navigate their fertility journey with holistic digital support. [10]

FDA Guidance: The Innovator’s Green Light 

The U.S. Food and Drug Administration (FDA) has taken major steps to clarify how digital and AI-based solutions can be regulated and commercialized. Of note, five recent guidance areas are especially relevant:

1. AI-Enabled Software Lifecycle Guidance 

Outlines a risk-based framework for using AI in drug development and regulatory submissions, including principles of transparency and model validation [1]. (Draft, Jan 2025)

2. Framework for Digital Health Technologies (DHTs) in Drug Development

Issued under PDUFA VII, this guidance supports the structured use of sensors, wearables, and apps during clinical trials [2].

3. Guidance on Remote Data Acquisition 

Supports decentralized clinical trials and real-time data capture from patients outside clinical settings [3]. (Final, Dec 2023)

4. Software as a Medical Device (SaMD) and Cybersecurity Guidance 

Outlines expectations for secure lifecycle development, threat modeling, and software transparency across all software-based medical devices [9]. (Final, June 2025)

5. Integrated Labeling

Signals the FDA’s willingness to allow digital companion apps to be co-labeled with medications, supporting true drug and software therapeutic innovation [8]. (PDURS, Draft)

Implications for the Industry

• Prescription Digital Therapeutics (PDTs) must meet rigorous SaMD regulatory requirements, including evidence of efficacy.
• Pharma-digital-medtech innovator partnerships are becoming more viable, supported by FDA policy shifts and payer interest in real-world data.
• Decentralized trials and RPM-based monitoring now have a formal regulatory path.
• Cybersecurity and AI governance must be embedded from the earliest stages of product development.

A Call to Action

The convergence of AI, biopharma and medtech innovation, and digital therapeutics presents a historic opportunity. For the first time, we can create an intelligent therapeutic ecosystem—one where every dose, every data point, and every patient touchpoint can drive better outcomes, inform innovation, and enhance access.

I’ve led programs at two companies that explored this path—one early in the market’s evolution, and another with wide prescriber and payer support. While outcomes varied, both efforts proved the model is not only viable—it’s inevitable.

With maturing infrastructure, regulatory clarity, payer alignment, and patient readiness, now is the time. Let’s work together to build digital programs that truly deliver on the promise of AI in healthcare.

Reach out to discuss implementation strategies that work by visiting JL Estep Consulting, by our contact form here, or via direct email.

Author

Jennifer Estep is a global biopharma and medtech executive with over 15 years of leadership in commercial strategy, digital health, and product innovation. As Principal of JL Estep Strategic Biopharma & MedTech Consulting, she advises on go-to-market, AI-driven clinical optimization, and value-based access. Jennifer is passionate about translating complex science into positive business and patient-centered impact across oncology, rare disease, and connected therapeutics.

---

References 

1. U.S. Food and Drug Administration. Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. Draft Guidance, Jan. 2025, https://www.fda.gov/media/177781/download.
2. U.S. Food and Drug Administration. Framework for the Use of Digital Health Technologies (DHTs) in Drug and Biological Product Development. 2023, https://www.fda.gov/drugs/development-resources/framework-use-digital-health-technologies-drug-and-biological-product-development.
3. U.S. Food and Drug Administration. Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. Final Guidance, Dec. 2023, https://www.fda.gov/media/155022/download.
4. Oliver Wyman Health. “FDA Guidance May Jumpstart the Digital Therapeutics Market.” Oliver Wyman, Nov. 2023, https://www.oliverwyman.com/our-expertise/perspectives/health/2023/november/fda-guidance-may-jumpstart-digital-therapeutics-market.html.
5. Axios. “FDA Pushes Drugmakers to Pair Pills with Digital Health Tools.” Axios, 29 Oct. 2024, https://www.axios.com/2024/10/29/patient-apps-prescription-drugs-software.
6. U.S. Food and Drug Administration. Prescription Drug-Use-Related Software (PDURS). Draft Regulatory Initiative, 2024.
7. JAMA Network. “Use of Wearable and Digital Health Technologies in Decentralized Clinical Trials: Benefits and Challenges.” JAMA, vol. 330, no. 15, 2023, pp. 1423–1432, https://jamanetwork.com/journals/jama/fullarticle/2809641.
8. Rejoyn by Otsuka and Click Therapeutics. “FDA Clears Rejoyn: First Prescription Digital Therapeutic for MDD.” Otsuka US, 2023, https://www.otsuka-us.com/news/fda-clears-rejoyn-digital-therapeutic-mdd.
9. U.S. Food and Drug Administration. Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions. Final Guidance, June 2025, https://www.fda.gov/media/166683/download.
10. Carrot Fertility. Sprints: Personalized Digital Support for Every Fertility Journey. Carrot Fertility, https://www.get-carrot.com/fertility-benefit-solution/sprints. Accessed 30 July 2025.